Clinical Trials
2 trialsNCT00084487 2014-05-23
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00006017 2010-06-10
Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Completed